Tag: pediatric drugs market outlook

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Pediatric Drugs Market?

There has been a swift increase in the pediatric drugs market dimensions in the past few years. The market, which was valued at $157 billion in 2024, is projected to increase to $179.43 billion in 2025, with a CAGR of 14.3%. The historic period’s growth is due to an increased requirement for related drugs, a higher pediatric population, more awareness about pediatric illnesses, expansion in pediatric oncology, advancements in digital health and telemedicine, and increased partnerships in the development of pediatric drugs.

The growth of the pediatric drugs market size is anticipated to surge significantly in the upcoming years, expanding to “$ 308.57 billion in 2029” with a compound annual growth rate (CAGR) of 14.5%. Factors contributing to this growth during the forecast period include a growing pediatric population, an increasing prevalence of mental health problems among children, a high incidence of chronic diseases in children, a robust vaccination rate, and an escalating demand for pediatric mental health medications. The forecast period will also witness key trends such as personalized pediatric medicine, the incorporation of technology in pediatric drug delivery, telemedicine, digital health solutions, the enhancement of pediatric clinical trials, and collaboration between pediatricians and pharmacists.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Pediatric Drugs Market?

The rise in premature births is anticipated to fuel expansion in the pediatric drugs market. Investigations have revealed that the number of infants born prior to surpassing 37 weeks of pregnancy has been increasing significantly. This trend is most likely due to multiple factors such as mature maternal age, lifestyle-related choices, pre-existing health conditions, multiple births, and insufficient prenatal care. Pediatric medications are crucial for catering to the health and developmental needs of premature infants by providing targeted therapies for issues like respiratory difficulties, infections, and nutritional deficiencies. For example, a report by Tommy’s, a charity organization in the UK, disclosed that the proportion of premature live births in England and Wales rose to 7.9% in 2022, an increase from 7.5% in the previous year. This indicates a premature birth rate of over 53,000 babies in 2022. Therefore, the increasing trend in premature births is contributing to the growth of the pediatric drugs market.

How Is The Pediatric Drugs Market Organized By Different Segments?

The pediatric drugs market covered in this report is segmented –

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs)

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents

What Current And Upcoming Trends Are Shaping The Pediatric Drugs Market?

Major companies involved in the pediatric drugs market are directing their focus towards the development of novel drugs like completely human monoclonal antibodies. The aim is to elevate treatment outcomes and minimize the side effects for young patients. Fully human monoclonal antibodies are a product of human genetic sequences, reducing the potential for immune system reactions as opposed to chimeric or humanized monoclonal antibodies. These antibodies are created with the use of cutting-edge biotechnology techniques, such as transgenic mice embedded with human antibody genes or phage display technology. For instance, in August 2022, Johnson and Johnson, a pharmaceutical firm based in the US, obtained FDA approval for STELARA (ustekinumab), a treatment for pediatric patients aged six and above diagnosed with active psoriatic arthritis (PsA). This approval represents a major breakthrough as STELARA is the first biologic therapy to target interleukin-12 (IL-12) and interleukin-23 (IL-23), crucial cytokines relevant to inflammatory responses connected with autoimmune diseases. About 5-8% of children with chronic inflammatory arthritis suffer from active PsA, presenting symptoms like joint swelling and skin lesions.

Who Are The Primary Market Leaders In The Pediatric Drugs Market?

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report

How Do Regional Dynamics Influence The Pediatric Drugs Market Performance?

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21249&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Estimated Industry Valuation for the HERG Screening Sector?#_x000D_

The market size for pediatric drugs has seen brisk growth in the past few years, expanding from $157 billion in 2024, it is projected to reach $179.43 billion in 2025, with a compound annual growth rate (CAGR) of 14.3%. The substantial growth during the historical period was fueled by a need for corresponding medicines, a surge in the pediatric population, enhanced understanding of pediatric diseases, the extension of pediatric oncology, the advent of digital health and telemedicine, and escalated partnerships in the development of pediatric drugs._x000D_

_x000D_

Anticipations point towards a swift expansion for the pediatric drugs market in the coming years. It’s projected to escalate to “$308.57 billion in 2029 with a compound annual growth rate (CAGR) of 14.5%. This surge in the future timeline can be credited to factors such as a growing pediatric demographic, the increasing incidence of mental health concerns in children, the swell in chronic conditions amongst children, an elevated rate of vaccinations in minors, and a surge in the demand for pediatric mental health drugs. The forthcoming period will see trends like bespoke pediatric medicine, the inclusion of technology in pediatric drug distribution, telemedicine and digital healthcare solutions, improvement in pediatric clinical trials, and cooperative efforts between pediatricians and pharmacists._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The HERG Screening Market?#_x000D_

The increase in heart disorder patients is set to push forward the expansion of the HERG screening market. Heart disorders, also recognized as cardiovascular diseases, are a variety of conditions that can harm the heart and blood vessels, compromising the heart’s capacity to function correctly and potentially leading to severe health issues. Factors such as unhealthy lifestyles, an aging population, genetic predisposition, diabetes, and metabolic syndrome can give rise to these disorders. HERG screening enables the discovery of potential drug prospects, prevention of cardiac incidents that could cause fatal cardiac arrhythmias, especially torsade de pointes (TdP), and enhancement of patient results. For example, a May 2023 report by the US-based Centers for Disease Control and Prevention revealed that 1 in 20 adults aged 20 and above were afflicted with cardiovascular diseases, with 695,000 persons living with these diseases and 375,476 persons dying from them. Moreover, a report from the UK-based Office for National Statistics published in March 2022 stated that 20,061 individuals died from heart attacks, indicating an increase from the previous year. As such, the surge in heart disorder patients is contributing to the escalation of the HERG screening market._x000D_

_x000D_

_x000D_

The pediatric drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs_x000D_

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels_x000D_

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids _x000D_

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs) _x000D_

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives _x000D_

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents_x000D_

_x000D_

#What Notable Trends Are Shaping The Direction Of The HERG Screening Market?#_x000D_

Leaders in the pediatric drugs market, such as Johnson and Johnson, are prioritizing the development of groundbreaking drugs like entirely human monoclonal antibodies for enhanced treatments and reduced side effects in young patients. These antibodies, wholly drawn from human genetics, lower the risk of immune system reactions compared to part human monoclonal antibodies, being produced through sophisticated biotechnology techniques like transgenic mice with human antibody genes or phage display technology. In August 2022, FDA approval for STELARA (ustekinumab), a treatment for pediatric patients who are six years or older suffering from active psoriatic arthritis (PsA) was achieved by Johnson and Johnson. This marked a significant milestone as STELARA is the inaugural biologic therapy that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), central cytokines in inflammatory responses linked with autoimmune diseases. Active PsA is a rare condition in children with chronic inflammatory arthritis, affecting approximately 5-8% of them and causing symptoms like joint swelling and skin lesions._x000D_

_x000D_

#Which Companies Currently Dominate The Competitive Landscape In The HERG Screening Industry?#_x000D_

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Driving Demand In The HERG Screening Market?#_x000D_

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21249&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Pediatric Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market size of pediatric drugs has witnessed a swift expansion in the past years. The growth is projected to continue, as it is set to advance from $157 billion in 2024 to $179.43 billion in 2025, riding on a compound annual growth rate (CAGR) of 14.3%. Factors that contributed to this augment during the historical period include the escalating demand for pertinent drugs, a surge in the pediatric populace, heightened cognizance of pediatric ailments, enlargement of pediatric oncology, the advent of digital health and telemedicine, as well as an upsurge in collaboration concerning pediatric drug evolution._x000D_

_x000D_

The market size of pediatric drugs is anticipated to swiftly expand in the subsequent few years, projected to reach $308.57 billion in 2029 with a compound annual growth rate (CAGR) of 14.5%. The forecasted growth can be associated with a surge in the pediatric population, escalating frequency of pediatric mental health problems, an increase in the number of children suffering from chronic diseases, elevated vaccination rates among children, and growing demand for pediatric mental health medicines. The key trends observable in this forecast period comprise bespoke pediatric medicine, the incorporation of technology in pediatric drug administration, telemedicine along with digital health solutions, improved pediatric clinical trials and cooperative efforts between pediatricians and pharmacists._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Pediatric Drugs Industry?#_x000D_

The escalation in the number of premature deliveries is projected to accelerate the expansion of the pediatric drugs market. Premature births are referred to those newborns who are born prior to the 37 weeks of gestation, as opposed to the normal 40-week term. This rise in preterm births is allied to elements such as elevated maternal age, lifestyle decisions, medical complications, multiple gestations, and insufficient prenatal attention. Pediatric medicines play a crucial role in promoting the health and growth of premature babies by presenting specialized treatments for problems such as respiratory ailments, infections, and dietary deficiencies. For instance, as per a report released by Tommy’s, a charitable entity based in the UK, in December 2022, the rate of premature live births in England and Wales escalated to 7.9% in 2022 from 7.5% in 2021. This indicates that over 53,000 babies were born prematurely in 2022. Consequently, the surge in preterm births is contributing to the growth of the pediatric drugs market._x000D_

_x000D_

#How Is the Pediatric Drugs Market Segmented?#_x000D_

The pediatric drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs_x000D_

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels_x000D_

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids _x000D_

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs) _x000D_

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives _x000D_

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21249&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Pediatric Drugs Market Growth?#_x000D_

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Pediatric Drugs Industry?#_x000D_

Leading firms in the pediatric drugs market are channeling their efforts towards the creation of novel drugs like fully human monoclonal antibodies, with the aim to enhance treatment results and lessen adverse effects in children. Fully human monoclonal antibodies are formulated entirely from human genetic sequences, thereby reducing the probability of immune system responses when contrasted with chimeric or humanized monoclonal antibodies. Advanced biotechnology methodologies such as transgenic mice with human antibody genes or phage display technology are utilized to produce these antibodies. For instance, in August 2022, Johnson and Johnson, a pharmaceutical enterprise based in the US, gained FDA approval for STELARA (ustekinumab), a medication purposed to treat pediatric patients six years and older afflicted by active psoriatic arthritis (PsA). The approval signifies a substantial progression as STELARA is the inaugural and sole biologic therapy directed at interleukin-12 (IL-12) and interleukin-23 (IL-23), primary cytokines implicated in the inflammatory processes connected with autoimmune diseases. Active PsA is a rare disorder affecting roughly 5-8% of children with chronic inflammatory arthritis, culminating in symptoms such as joint swelling and skin lesions._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report_x000D_

_x000D_

#How Is the Pediatric Drugs Market Defined and What Are Its Core Parameters?#_x000D_

Pediatric drugs are medications specifically formulated, dosed, or approved for use in infants, children, and adolescents. These drugs are designed to treat various medical conditions in pediatric patients, considering their unique physiological and metabolic differences from adults._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21249_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pediatric Drugs Market Size Changed, over the years?

Recent years have seen the pediatric drugs market expand swiftly. Its size is projected to increase from $157.0 billion in 2024, to $181.02 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.3%. The considerable growth in the previous timeline can be linked to the increasing demand for corresponding medicines, a higher pediatric populace, better knowledge and recognition of pediatric ailments, the development of pediatric oncology, the advent of digital health and telemedicine, and intensified collaboration in the formulation of pediatric drugs.

How Much Will the Pediatric Drugs Market Be Worth in 2029?

The market for pediatric drugs is predicted to experience significant expansion in the upcoming years, expecting to reach $316.0 billion in 2029, with a compound annual growth rate (CAGR) of 14.9%. This surge during the forecast period can be attributed to several factors, such as an increase in the pediatric population, a surge in pediatric mental health disorders, a rise in chronic conditions among children, elevated vaccination rates among children, and an increased demand for pediatric mental health medications. Key trends anticipated in the forecast period include individualized pediatric medications, the integration of technology in pediatric drug delivery, the use of telemedicine and digital health solutions, improvements in pediatric clinical trials, and the collaboration of pediatricians and pharmacists.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp

Which is the Largest Company in the Pediatric Drugs Market?

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila

What Are the Main Market Drivers in the Pediatric Drugs Industry?

An increase in preterm births, babies born prior to the 37th week of gestation rather than the standard 40 weeks, is anticipated to boost the expansion of the pediatric drugs market. This surge in early deliveries is related to a multitude of factors including advanced maternal age, lifestyle factors, pre-existing health conditions, multiple gestations, and insufficient prenatal care. Pediatric drugs play a crucial role in fostering the health and growth of premature infants, by providing specialized treatments for issues such as respiratory complications, infections, and nutritional deficiencies. As per a report released by Tommy’s, a charity organization from the UK, in December 2022, there was an increase in the rate of premature live births in England and Wales from 7.5% in 2021 to 7.9% in 2022, equating to over 53,000 premature births in 2022. Subsequently, this upswing in preterm births is sparking the development of the pediatric drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21249&type=smp

How Is the Pediatric Drugs Market Segments Structured?

The pediatric drugs market covered in this report is segmented –

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs)

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents

What Strategic Trends Are Transforming the Pediatric Drugs Market?

Leading pediatric drug market firms are concentrating on creating innovative medicines, like fully human monoclonal antibodies, to enhance treatment results and limit side effects in young patients. A fully human monoclonal antibody (mAb) is entirely formed from human genetic sequences, thus reducing the likelihood of immune system responses compared to chimeric or humanized monoclonal antibodies. These antibodies are created using sophisticated biotech methods, such as transgenic mice carrying human antibody genes or phage display technology. For example, in August 2022, Johnson and Johnson, an American pharmaceutical firm, obtained FDA approval for STELARA (ustekinumab) to treat pediatric patients six years and older suffering active PsA. This approval is a milestone since STELARA is the first and only biologic therapy that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial cytokines involved in the inflammatory responses connected with autoimmune diseases. Active PsA is an uncommon condition influencing about 5-8% of kids with chronic inflammatory arthritis, causing symptoms like joint swelling and skin lesions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report

Which Global Regions Offer the Highest Growth in the Pediatric Drugs Market?

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21249

This Report Delivers Insight On:

1. How big is the pediatric drugs market, and how is it changing globally?

2. Who are the major companies in the pediatric drugs market, and how are they performing?

3. What are the key opportunities and risks in the pediatric drugs market right now?

4. Which products or customer segments are growing the most in the pediatric drugs market?

5. What factors are helping or slowing down the growth of the pediatric drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#How Has The Pediatric Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market size for pediatric drugs has seen a swift expansion in the past few years. The market which stood at $157.0 billion in 2024 is projected to reach $181.02 billion in 2025, marking a compound annual growth rate (CAGR) of 15.3%. This considerable growth during the historical period can be associated with factors such as the increasing demand for corresponding medicines, a surge in the pediatric population, heightened awareness of pediatric diseases, expansion in the field of pediatric oncology, the emergence of digital health and telemedicine, and amplified collective efforts in the realm of pediatric drug development._x000D_

_x000D_

The market size for pediatric drugs is projected to undergo a swift expansion in the ensuing years, reaching $316.0 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 14.9%. The acceleration for the forecast period can be credited to factors such as an increasing pediatric demographic, escalating incidents of pediatric mental disorders, a rising count of children suffering from chronic diseases, augmented child vaccination rates, and a growing demand for pediatric mental health drugs. Key trends for the forecast phase include personalized pediatric treatment, the incorporation of technology in pediatric medicine delivery, the application of telemedicine and digital health aids, improvement in pediatric clinical examinations, and teamwork between pediatric specialists and pharmacists._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp_x000D_

_x000D_

#Which Primay Drivers Are Accelerating Growth in the Pediatric Drugs Market?#_x000D_

The pediatric drugs market is anticipated to see significant progress due to the rising instances of preterm births. Babies who are born before the standard gestation period of 40 weeks, specifically before 37 weeks, are classified as preterm. This surge in preterm births is linked to numerous factors like increased maternal age, certain lifestyle choices, existing medical conditions, multiple pregnancies, and lack of adequate prenatal care. Pediatric drugs play a key role in supporting the health and overall development of preterm babies as they offer specified treatments for issues such as respiratory complications, infections, and nutritional deficiencies. A December 2022 report from Tommy’s, a charity organization based in the UK, stated that preterm live births in England and Wales rose to 7.9% in 2022, from 7.5% in 2021. This translates to over 53,000 babies being born prematurely in 2022. Thus, the escalating number of preterm births is fueling the expansion of the pediatric drugs market._x000D_

_x000D_

#Which Primary Segments of the Pediatric Drugs Market Are Driving Growth and Industry Transformations?#_x000D_

The pediatric drugs market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs_x000D_

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels_x000D_

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids_x000D_

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs)_x000D_

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives_x000D_

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21249&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Pediatric Drugs Market?# Market?#_x000D_

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Which Technological Trends Are Reshaping the Pediatric Drugs Industry Dynamics?#_x000D_

Leading firms in the pediatric drugs market have shifted their focus towards creating innovative drugs like fully human monoclonal antibodies to enhance treatment results and reduce potential side effects for young patients. Fully human monoclonal antibodies are completely derived from human genetic sequences, reducing the likelihood of immune reactions compared to chimeric or humanized monoclonal antibodies. This kind of antibody is achieved through contemporary biotechnology methods, including the usage of transgenic mice with human antibody genes or phage display technology. In a notable development, Johnson and Johnson, an American pharmaceutical company, gained FDA approval for STELARA (ustekinumab), a treatment for pediatric patients six years and above with active Psoriatic Arthritis (PsA), in August 2022. This great stride is due to STELARA being the only biologic therapy in the market that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), critical cytokines in inflammatory responses connected to autoimmune diseases. Active PsA, a rare condition linked to chronic inflammatory arthritis, affects roughly 5-8% of children, leading to symptoms such as join swelling and skin lesions._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Pediatric Drugs Market?#_x000D_

Pediatric drugs are medications specifically formulated, dosed, or approved for use in infants, children, and adolescents. These drugs are designed to treat various medical conditions in pediatric patients, considering their unique physiological and metabolic differences from adults._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21249_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the pediatric drugs market?

The market size of pediatric drugs has seen swift growth in the recent past. It is predicted to expand from $157.0 billion in 2024 to $181.02 billion in 2025, with a compound annual growth rate (CAGR) of 15.3%. The surge in the historic phase can be ascribed to the increasing need for corresponding medications, high demand from the escalating pediatric population, improved awareness about pediatric diseases, the growth in pediatric oncology, the rise in digital health and telemedicine, and heightened cooperation in the development of pediatric drugs.

What will be the pediatric drugs market size in the future?

The pediatric medications market is anticipated to expand rapidly over the coming years, with a projected worth of $316.0 billion in 2029, marking a Compound Annual Growth Rate (CAGR) of 14.9%. The forecast period’s growth is due to increased child population, a surge in pediatric mental health disorders, a rise in chronic conditions among children, accelerated children vaccination rates, and an augmented demand for pediatric mental health drugs. Looking forward, key trends for the forecast period will likely involve individualized medicine for children, the implementation of technology in pediatric drug administration, the adoption of telemedicine and digital health solutions, the improvement of pediatric clinical trials, and cooperation between pediatricians and pharmacists.

Get your pediatric drugs market report here!

https://www.thebusinessresearchcompany.com/report/pediatric-drugs-global-market-report

What main drivers are fueling expansion in the pediatric drugs market?

Acceleration in the number of preterm births, where babies are born prior to 37 weeks of gestation instead of the average 40 weeks, is projected to fuel the expansion of the pediatric drugs market. Factors contributing to this surge in preterm births include increased age of mothers, lifestyle decisions, medical conditions, multiple pregnancies, and lack of appropriate prenatal care. Pediatric drugs play a crucial role in promoting the health and growth of premature infants by providing specialized treatments for issues such as respiratory difficulties, infections, and nutritional deficiencies. For example, Tommy’s, a charity organization based in the UK, published a report in December 2022 stating that the percentage of live premature births in England and Wales had risen to 7.9% in 2022 from 7.5% in 2021, accounting for more than 53,000 preterm babies born in 2022. Thus, the increasing prevalence of preterm births is propelling the pediatric drugs market’s growth.

What key areas define the segmentation of the global pediatric drugs market?

The pediatric drugs market covered in this report is segmented –

1) By Type: Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs

2) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Respiratory Disorder Drugs: Asthma Medications, Cystic Fibrosis Treatments, Bronchodilators, Corticosteroids

2) By Autoimmune Disorder Drugs: Immunosuppressants, Biologic Therapies, Disease-Modifying Antirheumatic Drugs (DMARDs)

3) By Gastrointestinal Drugs: Proton Pump Inhibitors (PPIs), Antiemetics, Antidiarrheals, Laxatives

4) By Cardiovascular Drugs: Antihypertensive Medications, Heart Failure Treatments, Antiarrhythmic Drugs, Lipid-lowering Agents

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21249&type=smp

Who are the dominant players expanding their reach in the pediatric drugs market?

Major companies operating in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila

What emerging trends are influencing the growth of the pediatric drugs market?

Major players in the pediatric drugs market are investing in creating groundbreaking drugs like wholly human monoclonal antibodies, with the aim of enhancing treatment results and reducing side effects for pediatric patients. Wholly human monoclonal antibodies are antibodies completely derived from human genetic sequences, thereby reducing the likelihood of immune system reactions, in contrast to chimeric or humanized monoclonal antibodies. These antibodies are manufactured using state-of-the-art biotechnology methods like transgenic mice embedded with human antibody genes or phage display technology. As an example, in August 2022, Johnson and Johnson, a pharmaceutical company based in the US, obtained FDA endorsement for STELARA (ustekinumab) for treating pediatric patients six years and older with active psoriatic arthritis (PsA). This endorsement marks considerable progress, as STELARA is the sole biologic treatment targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), essential cytokines taking part in inflammatory responses related to autoimmune ailments. Active PsA is a rare disorder impacting about 5-8% of children suffering from chronic inflammatory arthritis, causing symptoms like joint swelling and skin lesions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21249

Which regions are emerging as leaders in the pediatric drugs market?

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Water-Soluble Vitamin And Mineral Feed Supplements Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/water-soluble-vitamin-and-mineral-feed-supplements-global-market-report

Gummy Vitamins Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gummy-vitamins-global-market-report

Cell and Gene Therapy Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: